Free Trial

Kornitzer Capital Management Inc. KS Purchases 14,870 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

ADMA Biologics logo with Medical background

Kornitzer Capital Management Inc. KS grew its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 45.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,870 shares of the biotechnology company's stock after purchasing an additional 14,870 shares during the period. Kornitzer Capital Management Inc. KS's holdings in ADMA Biologics were worth $950,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in ADMA Biologics by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock worth $312,109,000 after buying an additional 80,302 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of ADMA Biologics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock valued at $93,187,000 after acquiring an additional 50,399 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after purchasing an additional 643,661 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of ADMA Biologics by 2.8% in the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company's stock worth $64,654,000 after purchasing an additional 102,692 shares during the last quarter. Finally, Oberweis Asset Management Inc. increased its position in shares of ADMA Biologics by 15.0% in the fourth quarter. Oberweis Asset Management Inc. now owns 3,342,560 shares of the biotechnology company's stock worth $57,325,000 after purchasing an additional 435,480 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ADMA. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial lifted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th.

Check Out Our Latest Stock Report on ADMA

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director directly owned 94,830 shares in the company, valued at $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock valued at $9,644,269 over the last three months. Insiders own 3.50% of the company's stock.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $17.69 on Thursday. The firm has a market capitalization of $4.22 billion, a PE ratio of 20.81 and a beta of 0.43. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. ADMA Biologics Inc has a 12 month low of $10.21 and a 12 month high of $25.67. The business's 50-day moving average price is $19.36 and its 200-day moving average price is $18.76.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company's revenue was up 40.2% compared to the same quarter last year. During the same period last year, the business posted $0.08 earnings per share. Sell-side analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

About ADMA Biologics

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Articles

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ADMA Biologics Right Now?

Before you consider ADMA Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.

While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Time to Cash Out? 5 Stocks to Drop Before Earnings
Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines